HSD3B and Gene-Gene Interactions in a Pathway-Based Analysis of Genetic Susceptibility to Bladder Cancer

Bladder cancer is the 4th most common cancer among men in the U.S. We analyzed variant genotypes hypothesized to modify major biological processes involved in bladder carcinogenesis, including hormone regulation, apoptosis, DNA repair, immune surveillance, metabolism, proliferation, and telomere maintenance. Logistic regression was used to assess the relationship between genetic variation affecting these processes and susceptibility in 563 genotyped urothelial cell carcinoma cases and 863 controls enrolled in a case–control study of incident bladder cancer conducted in New Hampshire, U.S. We evaluated gene–gene interactions using Multifactor Dimensionality Reduction (MDR) and Statistical Epistasis Network analysis. The 3′UTR flanking variant form of the hormone regulation gene HSD3B2 was associated with increased bladder cancer risk in the New Hampshire population (adjusted OR 1.85 95%CI 1.31–2.62). This finding was successfully replicated in the Texas Bladder Cancer Study with 957 controls, 497 cases (adjusted OR 3.66 95%CI 1.06–12.63). The effect of this prevalent SNP was stronger among males (OR 2.13 95%CI 1.40–3.25) than females (OR 1.56 95%CI 0.83–2.95), (SNP-gender interaction P = 0.048). We also identified a SNP-SNP interaction between T-cell activation related genes GATA3 and CD81 (interaction P = 0.0003). The fact that bladder cancer incidence is 3–4 times higher in males suggests the involvement of hormone levels. This biologic process-based analysis suggests candidate susceptibility markers and supports the theory that disrupted hormone regulation plays a role in bladder carcinogenesis.

[1]  Ting Hu,et al.  Characterizing genetic interactions in human disease association studies using statistical epistasis networks , 2011, BMC Bioinformatics.

[2]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[3]  J. Koch,et al.  Mechanisms of Tumor and Viral Immune Escape from Natural Killer Cell-Mediated Surveillance , 2011, Journal of Innate Immunity.

[4]  K. Dietrich,et al.  Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. , 2011, European journal of cancer.

[5]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[6]  William Wheeler,et al.  A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci , 2010, Nature Genetics.

[7]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[8]  Jason H. Moore,et al.  Spatially Uniform ReliefF (SURF) for computationally-efficient filtering of gene-gene interactions , 2009, BioData Mining.

[9]  Tony Fletcher,et al.  Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. , 2009, Cancer research.

[10]  T. Cotter,et al.  Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.

[11]  I. Thompson,et al.  Single and Multigenic Analysis of the Association between Variants in 12 Steroid Hormone Metabolism Genes and Risk of Prostate Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[12]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[13]  Arthur C. Sanderson,et al.  Bladder cancer SNP panel predicts susceptibility and survival , 2009, Human Genetics.

[14]  Tony Fletcher,et al.  Sequence variant on 8q24 confers susceptibility to urinary bladder cancer , 2008, Nature Genetics.

[15]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[16]  K. E. Visser.  Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? , 2008, Cancer Immunology, Immunotherapy.

[17]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[18]  N. Nock,et al.  SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness , 2007, The Prostate.

[19]  C. Perou,et al.  Common Genetic Variation in GATA-Binding Protein 3 and Differential Susceptibility to Breast Cancer by Estrogen Receptor α Tumor Status , 2007, Cancer Epidemiology Biomarkers & Prevention.

[20]  R. Weinshilboum,et al.  Human 3β-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  M. Kogevinas,et al.  Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study , 2007, BMC urology.

[22]  T. Griffith,et al.  Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer , 2007, Immunologic research.

[23]  J. Reichardt,et al.  Genomic biomarkers, androgen pathway and prostate cancer. , 2007, Pharmacogenomics.

[24]  Robert J. Marinelli,et al.  Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA Microarray , 2007, The American journal of surgical pathology.

[25]  E. Messing,et al.  Promotion of bladder cancer development and progression by androgen receptor signals. , 2007, Journal of the National Cancer Institute.

[26]  Liang Cheng,et al.  Bladder cancer: epidemiology, staging and grading, and diagnosis. , 2005, Urology.

[27]  Jason H Moore,et al.  Computational analysis of gene-gene interactions using multifactor dimensionality reduction , 2004, Expert review of molecular diagnostics.

[28]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[29]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[30]  Jason H. Moore,et al.  Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions , 2003, Bioinform..

[31]  Jason H. Moore,et al.  Power of multifactor dimensionality reduction for detecting gene‐gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity , 2003, Genetic epidemiology.

[32]  J. Carpten,et al.  Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. , 2002, Cancer research.

[33]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[34]  S. Levy,et al.  Anti‐CD81 activates LFA‐1 on T cells and promotes T cell–B cell collaboration , 2001, European journal of immunology.

[35]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[36]  T. Tosteson,et al.  Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. , 1998, Environmental health perspectives.

[37]  P. Hartge,et al.  Familial and environmental interactions in bladder cancer risk , 1985, International journal of cancer.

[38]  J. W. Sullivan,et al.  Epidemiologic survey of bladder cancer in greater New Orleans. , 1982, The Journal of urology.

[39]  R. Cartwright.  Genetic association with bladder cancer. , 1979, British medical journal.

[40]  Jian Gu,et al.  Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[41]  K. D. de Visser.  Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? , 2008, Cancer immunology, immunotherapy : CII.

[42]  C. Perou,et al.  Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status. , 2007, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  R. Weinshilboum,et al.  Human 3beta-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics. , 2007, The Journal of steroid biochemistry and molecular biology.

[44]  Jason H. Moore,et al.  Ideal discrimination of discrete clinical endpoints using multilocus genotypes , 2004, Silico Biol..

[45]  C. Lynch,et al.  Bladder cancer, parity, and age at first birth , 2004, Cancer Causes & Control.

[46]  H. Bartsch,et al.  Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. , 1999, Cancer detection and prevention.